SEOUL: South Korea plans to mass-produce an antibody treatment of the novel coronavirus later this month, health authorities said Tuesday.
The country's drug ministry is currently reviewing phase 2/3 clinical tests for the antibody-based treatment and aims to mass-produce commercial antibodies for the novel coronavirus in September, according to Kwon Jun-wook, deputy chief at the Central Disease Control Headquarters.
Health researchers are currently analysing results of the phase 1 trial, which was approved by the drug ministry on July 17.
They also earned approval for the phase 1 study of the treatment in Britain on July 29.
For blood plasma-based treatment, health authorities said the drug ministry approved the phase 2 study of its development on August 20, and six medical institutions, including Samsung Medical Centre and Asan Medical Centre, will verify its effectiveness and safety on COVID-19 patients.
Health authorities added the blood plasma material for the phase 2 trial will begin being produced Tuesday and supply of the substance will be completed in mid-October.
Discussions of trade, climate change and international security will run up against the sharp US policy changes
Man-Yi, sixth storm to hit country in span of one month, made landfall in eastern province of Catanduanes on Saturday
Around 200 primates escaped their enclosures, causing mayhem through Lopburi in Thailand
Interim leader Yunus says his administration focused on ensuring those guilty of cracking down on protests faced justice
Police allege offences took place between 2001, 2019 against 8 victims, some of whom Jones knew
Veteran legislator Vijitha Herath to helm the foreign affairs ministry
